Vaxart, Inc. (VXRT)
OTC Markets OTCQX · USD · Healthcare · Biotechnology
$0.40 (-1.23%) as of
Key statistics
- Market cap
- 97.48M
- P/E (TTM)
- 2.35
- Forward P/E
- -0.39
- EPS (TTM)
- 0.1700
- Dividend yield
- 0.00%
- 52-week range
- 0.3100 – 0.8400
- Beta
- 1.06
- Revenue (TTM)
- 243.06M
- Profit margin
- 15.88%
- Analyst target
- $3.33
- Volume
- 31.23k
About Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- South San Francisco, CA, United States
- Employees
- 65
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.